Clinical outcomes of resected EGFR positive stage I-III NSCLC patients in the Midlands, UK

被引：0

作者：

Powell, R. L. ^{[1
]}

Murukesh, N. ^{[2
]}

Seeva, P. ^{[2
]}

Solanki, A. ^{[3
]}

Singh, A. ^{[3
]}

Jain, A. ^{[4
]}

Elmasry, A. R. ^{[5
]}

Jegannathen, A. ^{[5
]}

Irwin, A. ^{[6
]}

Ghafoor, Q. ^{[6
]}

O'Sullivan, B. ^{[6
]}

Taniere, P. ^{[7
]}

Baijal, S. ^{[8
]}

机构：

[1] Univ Hosp Birmingham NHS Fdn Trust, Clin Haematol & Oncol Dept, Heartlands Hosp, Birmingham, W Midlands, England

[2] Worcestershire Royal Hosp, Dept Oncol, Worcester, England

[3] Royal Wolverhampton NHS Trust, New Cross Hosp, Deanesly Ctr, Wolverhampton, England

[4] New Cross Hosp, Royal Wolverhampton Hosp NHS Trust, Wolverhampton, England

[5] Univ Hosp North Midlands, Stoke On Trent, Staffs, England

[6] New Queen Elizabeth Hosp Birmingham, Oncol, Birmingham, W Midlands, England

[7] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England

[8] Heart England NHS Fdn Trust, Heartlands Hosp, Birmingham, W Midlands, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

67P

引用

页码：S731 / S732

页数：2

共 50 条

[21] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
James E. Frampton
Targeted Oncology, 2022, 17 : 369 - 376
[22] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
Frampton, James E.
TARGETED ONCOLOGY, 2022, 17 (03) : 369 - 376
[23] Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Wolfgang Schuette
Peter Schirmacher
Wilfried E. E. Eberhardt
Manfred Dietel
Ute Zirrgiebel
Lars Muehlenhoff
Michael Thomas
BMC Cancer, 18
[24] Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Schuette, Wolfgang
Schirmacher, Peter
Eberhardt, Wilfried E. E.
Dietel, Manfred
Zirrgiebel, Ute
Muehlenhoff, Lars
Thomas, Michael
BMC CANCER, 2018, 18
[25] ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts)
Rosell, R
de Lena, M
Carpagnano, F
Ramlau, R
Gonzalez-Larriba, J
Grodzki, T
Le Groumellec, A
Aubert, D
Gasmi, J
Douillard, J
LUNG CANCER, 2005, 49 : S3 - S4
[26] Utility of PET/CT in patients with stage I-III melanoma
Aviles Izquierdo, J. A.
Molina Lopez, I.
Sobrini Morillo, P.
Marquez Rodas, I.
Mercader Cidoncha, E.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (08): : 1414 - 1417
[27] Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Blackhall, Fiona H.
Peters, Solange
Bubendorf, Lukas
Dafni, Urania
Kerr, Keith M.
Hager, Henrik
Soltermann, Alex
O'Byrne, Kenneth J.
Dooms, Christoph
Sejda, Aleksandra
Hernandez-Losa, Javier
Marchetti, Antonio
Savic, Spasenija
Tan, Qiang
Thunnissen, Erik
Speel, Ernst-Jan M.
Cheney, Richard
Nonaka, Daisuke
de Jong, Jeroen
Martorell, Miguel
Letovanec, Igor
Rosell, Rafael
Stahel, Rolf A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2780 - +
[28] Survival of clinical stage I-III rectal cancer patients: a population-based comparison
Joye, I.
Silversmit, G.
Van Eycken, E.
Debucquoy, A.
Vandendael, T.
Penninckx, F.
Haustermans, K.
RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S108 - S109
[29] Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
Liao, B-C.
Bai, Y-Y.
Lin, C-C.
Lin, S-Y.
Lee, Y-F.
Ho, C-C.
Shih, J-Y.
Chang, Y-C.
Yu, C-J.
Yang, J.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S123 - S124
[30] Outcomes of patients with stage III (clinical N2) NSCLC: A VACCR analysis
Ganti, A.
Gonsalves, W.
Aldoss, I.
Loberiza, F. R., Jr.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →